Analyst Coverage Initiated: NUVL rating Outperform by BMO Capital Markets
Price Target: $28
Report Date: 06-24-2022
Symbol: NUVL - Nuvalent, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: NUVL rating Outperform by BMO Capital Markets
Price Target: $28
Nuvalent, Inc. (NUVL)
One Broadway
Cambridge, MA 02142
Phone: 857-357-7000
Website: https://www.nuvalent.com
CEO:
NASDAQ, Nasdaq Global Select
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.